These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20960507)

  • 61. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer--incidence of neutropenic fever outside clinical trials.
    Passos-Coelho JL; Esteves S; Vieira PA; Isidoro M; Ribeiro M; Oliveira J; Moreira AR
    Breast J; 2011; 17(5):539-41. PubMed ID: 21899649
    [No Abstract]   [Full Text] [Related]  

  • 63. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):133-41. PubMed ID: 20036141
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S1-2. PubMed ID: 21600379
    [No Abstract]   [Full Text] [Related]  

  • 65. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight.
    Biglia N; Moggio G; Peano E; Sgandurra P; Ponzone R; Nappi RE; Sismondi P
    J Sex Med; 2010 May; 7(5):1891-900. PubMed ID: 20233281
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preoperative chemotherapy in the treatment of inflammatory breast cancer.
    Keiling R; Guiochet N; Calderoli H; Hurteloup P; Krzisch C
    Prog Clin Biol Res; 1985; 201():95-104. PubMed ID: 4095121
    [No Abstract]   [Full Text] [Related]  

  • 68. Transcranial direct current stimulation (TDCS) improved cognitive outcomes in a cancer survivor with chemotherapy-induced cognitive difficulties.
    Knotkova H; Malamud SC; Cruciani RA
    Brain Stimul; 2014; 7(5):767-8. PubMed ID: 25085269
    [No Abstract]   [Full Text] [Related]  

  • 69. Chemotherapy-related cognitive dysfunction.
    Wefel JS; Schagen SB
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):267-75. PubMed ID: 22453825
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Side effects expected and experienced by women receiving chemotherapy for breast cancer.
    Tierney AJ; Leonard RC; Taylor J; Closs SJ; Chetty U; Rodger A
    BMJ; 1991 Feb; 302(6771):272. PubMed ID: 1998793
    [No Abstract]   [Full Text] [Related]  

  • 71. Cancer treatment and cognitive function: chemotherapy is not the only culprit.
    Ganz PA
    Oncology (Williston Park); 2014 Sep; 28(9):804-6. PubMed ID: 25224481
    [No Abstract]   [Full Text] [Related]  

  • 72. [4th International Conference of Geriatric Oncology. Cancer in the Elderly].
    Tumori; 1998; 84(6):A6-11. PubMed ID: 10080687
    [No Abstract]   [Full Text] [Related]  

  • 73. Inflammatory breast carcinoma: the sphinx of breast cancer research.
    Cristofanilli M; Singletary ES; Hortobagyi GN
    J Clin Oncol; 2004 Jan; 22(2):381-3; author reply 383. PubMed ID: 14722054
    [No Abstract]   [Full Text] [Related]  

  • 74. Cancer- and treatment-related cognitive changes: what can we do now? What lies ahead?
    Bender CM; Merriman JD
    Oncology (Williston Park); 2014 Sep; 28(9):806-8. PubMed ID: 25224482
    [No Abstract]   [Full Text] [Related]  

  • 75. Hematopoietic growth factors in breast cancer--overview.
    Osborne CK
    Breast Cancer Res Treat; 1991 Dec; 20 Suppl():S1-2. PubMed ID: 1806028
    [No Abstract]   [Full Text] [Related]  

  • 76. The neurobiological basis of anti-cancer therapy induced cognitive dysfunction and the promising pharmacological modalities against the same.
    Revannasiddaiah S; Gupta M; Seam R; Gupta M
    J Cancer Res Ther; 2012; 8(1):162-3. PubMed ID: 22531545
    [No Abstract]   [Full Text] [Related]  

  • 77. Chemobrain: is it time to initiate guidelines for assessment and management?
    Patel SK; Hurria A; Mandelblatt JS
    Oncology (Williston Park); 2014 Sep; 28(9):809-10. PubMed ID: 25224483
    [No Abstract]   [Full Text] [Related]  

  • 78. Cognitive dysfunction in cancer patients likely not all due to chemotherapy.
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28521365
    [No Abstract]   [Full Text] [Related]  

  • 79. Reversible nail loss after cancer chemotherapy.
    Kumar L; Kochupillai V
    Acta Oncol; 1990; 29(4):471. PubMed ID: 2390273
    [No Abstract]   [Full Text] [Related]  

  • 80. Cancer-related cognitive impairment and wellbeing in patients with newly diagnosed aggressive lymphoma compared to population norms and healthy controls: an exploratory study.
    Gates P; Dhillon HM; Krishnasamy M; Wilson C; Gough K
    Support Care Cancer; 2024 Mar; 32(4):238. PubMed ID: 38512692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.